Stockreport

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF Terry Chrisomalis Investing Group Leader Follow Summary Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatmen [Read more]